ReviewCureus2026
Targeted Temperature Management in Cardiogenic Shock Survivors of Cardiac Arrest: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted temperature management (TTM) is the established standard of care for comatose patients following cardiac arrest, but its safety profile and effectiveness in the subset of patients developing cardiogenic shock are not well defined. Benefits of neuroprotection may be offset by hypothermia-induced hemodynamic instability. This review aimed to evaluate the impact of TTM on mortality and neurological outcomes, specifically in cardiac arrest survivors with cardiogenic shock. PubMed, EMBASE, and Cochrane Central were searched from inception to December 2025 for randomized controlled trials (RCTs) and observational studies comparing TTM (32°C-34°C) versus normothermia or no temperature control in adults with post-cardiac arrest cardiogenic shock. The primary outcome was all-cause mortality. Secondary outcomes included favorable neurological function and lactate clearance. Data were pooled using a random-effects model (DerSimonian-Laird). Certainty of evidence was assessed using GRADE (Grading of Recommendations Assessment, Development, and Evaluation). Five studies involving 1,446 patients were included (two RCT sub-analyses and three observational studies). The pooled risk ratio (RR) for all-cause mortality was 1.02 (95% confidence interval (CI) 0.89-1.17; p = 0.76), indicating no significant survival benefit with TTM. Significant heterogeneity was observed (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.